INRLF (Valneva SE) Moat Score: 6/10 (As of Jul. 02, 2026)


INRLF Valneva SE INRLF
60 GF Score
Price $2.62
GF Value $2.84
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Moat Score?

Valneva SE INRLF 60 Moat Score is 6 as of Jul. 02, 2026. GuruFocus rates INRLF with a GF Score™ of 60/100 and a GF Value™ of $2.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,400 Biotechnology companies, Valneva SE ranks better than 98.93% on this metric.

Valneva SE has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Valneva SE has Narrow Moat: Valneva SE has a strong narrow moat due to its valuable intellectual property and patents in vaccine development. The company benefits from significant regulatory barriers and consistent R&D capabilities, but lacks the scale and brand strength for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Valneva SE might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Valneva SE  (OTCPK:INRLF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Valneva SE Moat Score Related Terms

INRLF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Valneva SE's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Moat Score distribution charts can be found below:

* The bar in red indicates where Valneva SE's Moat Score falls into.


INRLF
60GF Score
Valneva SE INRLF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Valneva SE (INRLF) has a Moat Score of 6 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Valneva SE ranks #15 out of 1400 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Valneva SE's Moat Score too high?
Valneva SE's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Valneva SE's value of 6 is 200% above this industry median. Based on the distribution chart, Valneva SE ranks #15 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valneva SE has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #15 out of 1400 companies for Moat Score. This places Valneva SE in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Valneva SE's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.84, compared to a current price of $2.62 — trading 7.7% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Valneva SE's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Valneva SE (INRLF), the current Moat Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Moat Score: 6
  • GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
  • GF Score™: 60/100 with 6 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1400)

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score

Get the complete analysis for INRLF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.84
GF Value